On May 24, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older. The approval was…
New York (May 15, 2019) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of venetoclax (VENCLEXTA, AbbVie Inc. and Genentech, Inc.) for the treatment of adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic…
Founding Sponsor Southern Glazer’s Wine & Spirits to Present Hot Wine Trends of 2019 and Special Craft Whiskey Tasting Chicago, Il. (May 1, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma…
Rituximab (Rituxan) has long been the standard of care for many lymphoma patients with relapsed follicular lymphoma (FL) and marginal zone lymphoma (MZL). Researchers on the AUGMENT trial, a large-scale, multicenter study, sought to improve outcomes for this group of…
The Lymphoma Research Foundation is proud to announce a new partnership with Leukemia & Lymphoma, an international peer-reviewed journal with worldwide print and electronic distribution that publishes articles around key findings in clinical, translational and scientific research relating to hematological…
Miami Beach Philanthropic Community Supports LRF’s Mission to Eradicate Lymphoma and Serve Those Impacted by this Blood Cancer Miami, Fla. (March 28, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma…
Investment Supports Young Investigators Dedicated to Developing Patient Therapies and Lymphoma Cures New York, NY (March 20, 2019) – The Lymphoma Research Foundation (LRF) – the nation’s largest non-profit organization devoted to funding innovative lymphoma research and serving the lymphoma…
Every year the National Institutes of Health (NIH) and National Cancer Institute (NCI) are required to prepare for the President and the Congress its best professional judgment on the optimal funding needed to make the most rapid progress in the…
At the 2018 ASH Annual Meeting, Catherine Diefenbach, MD (New York University) – a past recipient of LRF’s Clinical Investigator Career Development Award – presented data from cooperative group ECOG-ACRIN’s clinical trial of a new combination of existing therapies ipilimumab…